We are always evolving in an ever-changing industry.

Keep up-to-date with PrECOG by visiting our news page regularly.

PrE0403 – Active

Now Open to Enrollment: PrE0403 Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy. NCT03113422

PrE0102 – Published

The results from the PrE0102 study, a Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy was published by Kornblum N, Zhao F, Manola J, et.al. The article appeared online before print in the Journal of Clinical Oncology on April […]